Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats.

Ejersted C, Andreassen TT, Oxlund H, Jørgensen PH, Bak B, Häggblad J, Tørring O, Nilsson MH

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Sept 1993Cited by 99 (Europe PMC)

PMID8237479DOI10.1002/jbmr.5650080910PepBankPUB-08237479

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH(1-34) treatment did not change body weight.
In plain wordsIn rats, PTH treatment did not change body weight.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBody weight
Study
ratn: not reported in source
Rat femora
Outcome group
Body weight · Metabolic and weight
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
No changes in the body weights and no changes in the lengths of the femora were observed after the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747901
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH(1-34) treatment did not change femoral length.
In plain wordsIn rats, PTH treatment did not change thigh bone length.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral length
Study
ratn: not reported in source
Rat femora
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
No changes in the body weights and no changes in the lengths of the femora were observed after the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747902
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH treatment increased femoral bending strength dose dependently.
In plain wordsIn rats, PTH increased thigh bone bending strength with increasing dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBending strength
Study
ratn: not reported in source
Rat femora
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9-12% increase in the cross-sectional area of the femoral diaphyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747903
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH treatment increased femoral stiffness dose dependently.
In plain wordsIn rats, PTH increased thigh bone stiffness with increasing dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral stiffness
Study
ratn: not reported in source
Rat femora
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9-12% increase in the cross-sectional area of the femoral diaphyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747904
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH treatment increased femoral diaphyseal cross-sectional area by 9-12%.
In plain wordsIn rats, PTH increased thigh bone shaft cross-sectional area by 9-12%.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDiaphyseal cross-sectional area
Study
ratn: not reported in source
Rat femora
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Measurements
Cross-sectional area increase
9 to 12%
PTH treatment
Source sentences
Summary
A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9-12% increase in the cross-sectional area of the femoral diaphyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747905
06AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH treatment did not influence bone deflection capability.
In plain wordsIn rats, PTH did not change bone bending capacity.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDeflection capability
Study
ratn: not reported in source
Rat femora
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
The deflection capability and energy absorption were not influenced by any of the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747906
07AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH treatment did not influence bone energy absorption.
In plain wordsIn rats, PTH did not change bone energy absorption.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEnergy absorption
Study
ratn: not reported in source
Rat femora
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
The deflection capability and energy absorption were not influenced by any of the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747907
08AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH(1-34) and PTH(1-84) had similar effects on femoral biomechanical properties.
In plain wordsIn rats, PTH(1-34) and PTH(1-84) had similar effects on thigh bone mechanical properties.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBiomechanical properties versus PTH(1-84)
Study
ratn: not reported in source
Rat femora
Comparator
PTH-(1-84)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
No differences were found between the effects of PTH-(1-34) or PTH-(1-84) on the biomechanical properties of the femora.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747908
09AnimalAnimal study (in vivo)Safety outcome
In rats, human PTH(1-84) treatment produced no observed change in body weight.
In plain wordsIn rats, human PTH(1-84) treatment produced no observed change in body weight.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeBody weight
Study
ratn: not reported in source
Rats
Outcome group
Body weight · Metabolic and weight
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
No changes in the body weights and no changes in the lengths of the femora were observed after the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747909
10AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) treatment produced no observed change in femoral length.
In plain wordsIn rats, human PTH(1-84) treatment produced no observed change in femoral length.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeFemoral length
Study
ratn: not reported in source
Rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
No changes in the body weights and no changes in the lengths of the femora were observed after the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747910
11AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) treatment increased femoral bending strength in a dose-related manner.
In plain wordsIn rats, human PTH(1-84) treatment increased femoral bending strength in a dose-related manner.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseFemoral bending strength
Study
ratn: not reported in source
Rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9-12% increase in the cross-sectional area of the femoral diaphyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747911
12AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) treatment increased femoral stiffness in a dose-related manner.
In plain wordsIn rats, human PTH(1-84) treatment increased femoral stiffness in a dose-related manner.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseFemoral stiffness
Study
ratn: not reported in source
Rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9-12% increase in the cross-sectional area of the femoral diaphyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747912
13AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) treatment increased femoral diaphyseal cross-sectional area by 9-12%.
In plain wordsIn rats, human PTH(1-84) treatment increased femoral shaft cross-sectional area by 9-12%.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseFemoral diaphyseal cross-sectional area
Study
ratn: not reported in source
Rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Measurements
Cross-sectional area increase
9 to 12%
femoral diaphyses
Source sentences
Summary
A dose-related increase in the bending strength and stiffness of the femora was found, and this increase in mechanical strength corresponds with a 9-12% increase in the cross-sectional area of the femoral diaphyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747913
14AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) treatment did not influence femoral deflection capability.
In plain wordsIn rats, human PTH(1-84) treatment did not change femoral bending flexibility.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeFemoral deflection capability
Study
ratn: not reported in source
Rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
The deflection capability and energy absorption were not influenced by any of the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747914
15AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) treatment did not influence femoral energy absorption.
In plain wordsIn rats, human PTH(1-84) treatment did not change femoral energy absorption.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeFemoral energy absorption
Study
ratn: not reported in source
Rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
The deflection capability and energy absorption were not influenced by any of the PTH treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747915
16AnimalAnimal study (in vivo)Efficacy outcome
In rats, human PTH(1-84) and PTH(1-34) did not differ in their effects on femoral biomechanical properties.
In plain wordsIn rats, human PTH(1-84) and PTH(1-34) did not differ in their effects on femoral mechanical properties.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeFemoral biomechanical properties
Study
ratn: not reported in source
Rats
Comparator
Human PTH(1-34)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.1, 3.3, 10, or 30 nmol/kg/day · 30 daysAs given in this study (rat).
Source sentences
Summary
No differences were found between the effects of PTH-(1-34) or PTH-(1-84) on the biomechanical properties of the femora.
1 context sentence(design, population, supporting numbers)
Summary · context
Groups of rats were treated with biosynthetic human PTH-(1-34) or PTH-(1-84), 1.1, 3.3, 10, or 30 nmol/kg/day for 30 days.
Report a problemFND-0823747916

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.